CSPC Central Institute of Pharmaceutical Research

CSPC Central Institute of Pharmaceutical Research serves as the primary research and development hub for CSPC Pharmaceutical Group, one of China's largest pharmaceutical enterprises. The institute focuses on the discovery and clinical development of innovative therapies across oncology, cardiovascular, and metabolic diseases. It leverages advanced technology platforms, including nanoparticle delivery systems, antibody-drug conjugates (ADCs), and mRNA-based drug development. With a global R&D footprint spanning China and the United States, the institute manages a diverse pipeline of over 300 projects, transitioning the group from a generic-focused manufacturer to an innovation-driven biopharmaceutical leader. Key achievements include the development of blockbuster products like Keaili (paclitaxel albumin-bound) and the advancement of several first-in-class and best-in-class candidates into late-stage clinical trials.